Financial Performance - Heren Technology reported a revenue of RMB 500 million for the fiscal year 2023, representing a year-over-year growth of 15%[20]. - The company achieved a net profit of RMB 80 million, which is an increase of 10% compared to the previous year[20]. - The company's operating revenue for 2024 was ¥406,010,685.79, a decrease of 7.57% compared to ¥439,252,256.21 in 2023[25]. - The net profit attributable to shareholders for 2024 was ¥39,296,818.30, showing a slight increase of 0.46% from ¥39,116,183.90 in 2023[25]. - The net cash flow from operating activities significantly dropped by 90.41% to ¥7,996,955.78 in 2024 from ¥83,375,495.06 in 2023[25]. - The total assets at the end of 2024 increased by 1.65% to ¥1,462,115,708.52 compared to ¥1,438,378,630.67 at the end of 2023[25]. - The net assets attributable to shareholders rose by 2.91% to ¥1,110,690,629.61 at the end of 2024 from ¥1,079,270,615.54 at the end of 2023[25]. - The company reported a basic earnings per share of ¥0.15 for both 2024 and 2023, indicating no change[25]. - The weighted average return on equity for 2024 was 3.59%, a slight decrease from 3.69% in 2023[25]. - Heren Technology's gross margin improved to 45%, up from 42% in the previous year, reflecting better cost management[20]. Dividend Distribution - The company plans to distribute a cash dividend of 0.25 RMB per 10 shares to all shareholders, based on a total of 262,560,141 shares[12]. - For the 2024 profit distribution plan, the company will distribute a cash dividend of 0.25 yuan per 10 shares, totaling approximately 6,564,003.53 yuan based on a share base of 262,560,141 shares[188]. - The cash dividend represents 100% of the total profit distribution amount, indicating a strong commitment to returning value to shareholders[189]. Market Strategy and Expansion - Heren Technology plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[20]. - The company aims to adapt to changes in national policies and macroeconomic conditions by continuing product and technology innovation and strengthening its market position[12]. - The company is actively working to establish a stable customer base by improving service quality and expanding its client resources[7]. - The company is focusing on the development of urban-level smart healthcare solutions, driven by policies such as the integration of medical services, insurance, and pharmaceuticals, which are expected to enhance the market for digital health cities[120][124]. Research and Development - The company is investing RMB 50 million in R&D for new digital health solutions, aiming to launch two new products by Q3 2024[20]. - The number of R&D personnel increased to 257 in 2024 from 247 in 2023, representing a growth of 4.05%[84]. - R&D investment amounted to ¥53,327,497.12 in 2024, accounting for 13.13% of operating revenue, compared to 12.79% in 2023[84]. - The company is developing a SaaS-based clinical information system aimed at improving hospital efficiency, ensuring data security, and enhancing patient care[81]. - A comprehensive SaaS lifecycle management system is in progress to connect patients, healthcare providers, and pharmacies, aiming to reduce costs and improve service quality[82]. Risk Management - The company faces risks related to major project implementation, which could significantly impact current operating performance if any major projects encounter issues[6]. - The company has a high customer concentration, primarily serving large and medium-sized medical institutions, which poses a risk if any major clients decide to terminate their cooperation[7]. - The company recognizes the risk of technology and talent loss in the software industry and is focused on retaining its core technical team through competitive compensation and training[10]. - The company aims to mitigate the risk of major client attrition by improving service quality and maintaining a market-oriented approach to stabilize its customer base[142]. Governance and Internal Control - The company has established a governance structure that ensures the protection of shareholder rights and compliance with relevant laws and regulations[199]. - The internal control system is continuously improved to enhance the company's operational standards[199]. - The company has implemented various measures to protect employee rights and ensure their health and safety[200]. - The company has established an independent financial department with a complete financial accounting system, adhering to the "Enterprise Accounting Standards" and ensuring independent financial decision-making[155]. Operational Challenges - The company is experiencing increased complexity in management control due to the expansion of its service offerings, which may affect its gross profit margin[9]. - The company is facing increased risks in project investment returns due to economic conditions and service fee collection models[113]. - The company has successfully won multiple large-scale projects, each exceeding 10 million yuan, including the Zhejiang Provincial People's Hospital and Gansu Southern Regional Medical Center projects[48]. Employee Management - The total number of employees at the end of the reporting period is 684, with 672 from the parent company and 12 from major subsidiaries[180]. - The total employee compensation for the year is 127.95 million yuan, accounting for 38.19% of the company's total costs[182]. - The company has a training plan aimed at enhancing employee skills and supporting sustainable development[183]. - Continuous investment in human resources is a core strategy, with a focus on effective planning and optimization of personnel allocation[140].

证券代码：300550 证券简称：和仁科技 公告编号：2025-002 浙江和仁科技股份有限公司 关于已披露日常经营合同收到中标通知书 的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江和仁科技股份有限公司（以下简称"和仁科技"或"公司"）于 2025 年 4 月 7 日披露了《关于日常经营合同预中标的提示性公告》（详见巨潮资讯网 http://www.cninfo.com.cn，公告编号：2025-001），公司近日收到新疆维吾尔 自治区政务服务和公共资源交易中心发出的《中标（成交）通知书》，和仁科技 被确定为"新疆维吾尔自治区中医医院智慧医院信息化建设项目"的中标人。 一、中标项目情况 浙江和仁科技股份有限公司董事会 2025 年 4 月 10 日 1、项目名称：新疆维吾尔自治区中医医院智慧医院信息化建设项目 2、采购人：新疆维吾尔自治区中医医院 3、采购代理机构：新疆维吾尔自治区政务服务和公共资源交易中心 4、项目中标金额报价：148,160,000 元。实际金额依据双方后续签订的合 同为准。 二、中标对公司的影响 若公司能顺利签订合同并且 ...

证券时报网讯，企查查APP显示，近日，浙江和众仁信科技有限公司成立，法定代表人为赵晨晖，注册 资本1亿元，经营范围包含：互联网数据服务；信息系统集成服务；数据处理服务；物联网技术服务； 物联网技术研发等。 企查查股权穿透显示，该公司由和仁科技等共同持股。 ...

二、董事会会议审议情况 经与会董事审议并在议案表决票上签字表决，审议通过如下议案： 1、审议通过《关于制定公司<舆情管理制度>的议案》 表决结果：7 票同意，0 票反对，0 票弃权 证券代码：300550 证券简称：和仁科技 公告编号：2024-043 浙江和仁科技股份有限公司 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江和仁科技股份有限公司（以下简称"公司"）第四届董事会第九次会议 于 2024 年 12 月 30 日以通讯表决方式召开。 召开本次会议的通知已于 2024 年 12 月 25 日以电子邮件形式送达各位董事。 本次董事会会议应出席董事 7 名，实际出席董事 7 名。会议由公司董事长赵晨晖 主持。会议的召集、召开及表决程序符合《公司法》等法律、法规、规范性文件 以及《公司章程》的有关规定。 《舆情管理制度》详见信息披露网站巨潮资讯网（http://www.cninfo.com.cn）。 三、备查文件 1、经与会董事签字并加盖董事会印章的董事会决议； 2、深交所要求的其他文件。 特此公 ...

浙江和仁科技股份有限公司 舆情管理制度 第一章 总则 第一条 为了提高浙江和仁科技股份有限公司 以下简称 公司"）应对各类 舆情的能力，建立快速反应和应急处置机制，及时妥善处理各类舆情对公司股价、 公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合法权益，根据 《深圳证券交易所创业板股票上市规则》和 《公司章程》等相关规定，特制订本 制度。 第二条 本制度所称舆情包括： 一）报刊、电视、网络等媒体对公司进行的报道； 二）社会上存在的已经或将给公司造成影响的传言或信息； 三）其他涉及公司信息披露且可能或者已经影响社会公众投资者投资取向， 造成股价异常波动的信息。 第二章 舆情管理的组织体系及其工作职责 第三条 公司应对各类舆情实行统一领导、统一组织、快速反应、协同应对。 第四条 公司成立舆情管理工作领导小组 以下简称 舆情工作组"），由公 司董事长任组长，董事会秘书担任副组长，成员由公司其他高级管理人员及相关 职能部门负责人组成。 第五条 舆情工作组是公司应对各类舆情处理工作的领导机构，统一领导公 司应对各类舆情的处理工作，就相关工作做出决策和部署，根据需要研究决定公 司对外发布信息，主要工作职责包括： ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥103,854,630.35, representing a slight increase of 0.11% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was ¥15,261,850.34, a decrease of 1.00% year-on-year, while the net profit after deducting non-recurring gains and losses was ¥14,913,618.66, down 1.94%[3]. - Year-to-date net profit attributable to shareholders decreased by 92.92% to ¥929,244.29, with a year-to-date revenue decline of 6.42% to ¥264,317,028.74[3]. - Total operating revenue for Q3 2024 was CNY 264,317,028.74, a decrease of 6.4% compared to CNY 282,449,005.28 in the same period last year[13]. - Net profit for Q3 2024 was CNY 522,947.40, significantly lower than CNY 13,004,310.86 in Q3 2023, indicating a decline in profitability[14]. - The total comprehensive income attributable to the parent company for Q3 2024 is CNY 929,244.29, a decrease from CNY 13,115,994.73 in the previous period[15]. Cash Flow and Liquidity - The company's cash flow from operating activities showed a net outflow of ¥115,425,086.86, a decrease of 20.33% compared to the previous year[3]. - The net cash flow from operating activities for Q3 2024 is -CNY 115,425,086.86, compared to -CNY 95,927,471.87 in the same period last year[17]. - Cash inflow from operating activities totaled CNY 131,808,331.68, down from CNY 252,632,718.17 in the previous year[17]. - Cash outflow from operating activities reached CNY 247,233,418.54, a decrease from CNY 348,560,190.04 year-over-year[17]. - As of September 30, 2024, the company's cash and cash equivalents amounted to ¥482,414,027.65, a decrease from ¥555,323,304.95 at the beginning of the period, representing a decline of approximately 13.1%[11]. - The cash and cash equivalents at the end of Q3 2024 amounted to CNY 476,886,509.12, compared to CNY 412,296,423.36 at the end of the previous year[17]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥1,435,932,726.15, reflecting a decrease of 0.17% from the end of the previous year[3]. - The total assets decreased slightly to CNY 1,435,932,726.15 from CNY 1,438,378,630.67, reflecting a stable asset base[13]. - The total liabilities decreased to CNY 353,013,879.33 from CNY 357,905,927.02, indicating a reduction in financial obligations[13]. - The company's equity attributable to shareholders decreased by 0.64% to ¥1,072,323,055.60 compared to the end of the previous year[3]. - The company's equity attributable to shareholders decreased to CNY 1,072,323,055.60 from CNY 1,079,270,615.54, reflecting the impact of lower profits[13]. Investments and Expenses - The company reported a significant increase in prepayments, which rose by 461.21% to ¥9,261,272.84, attributed to increased procurement payments[6]. - The company’s long-term equity investments surged by 165,945.17% to ¥3,166,049.62 due to increased investment in Zhongyuan Heren[6]. - The company experienced a 1557.92% increase in credit impairment losses, amounting to -¥22,538,003.98, primarily influenced by sales collection issues[6]. - The company reported a decrease in financial expenses by 53.33% to -¥4,025,806.35, mainly due to reduced interest income[6]. - Research and development expenses increased to CNY 38,564,331.96 from CNY 37,478,001.90, highlighting continued investment in innovation[14]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 9,299, with the largest shareholder, Tongce Medical Co., holding 19.01% of shares[8]. - The company reported a total of 295,230 restricted shares at the beginning of the period, with 51,450 shares released from restrictions during the period[9]. - The largest shareholder, Tongce Medical Co., held 49,920,315 shares, representing 19.01% of the total shares[8]. - The company has a total of 40,260,815 shares held by Hangzhou Panyuan Investment Co., accounting for 15.33% of the total shares[8]. Operational Changes - The company terminated the "Smart Hospital Integrated Construction Project" and will permanently supplement the remaining raised funds into working capital, following approval at the September 9, 2024, shareholders' meeting[10].

证券代码：300550 证券简称：和仁科技 公告编号：2024-042 浙江和仁科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江和仁科技股份有限公司（以下简称"公司"）为真实、准确、客观反映 公司的财务状况和经营成果，根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《企业会计准则》等相关规定，公司本着谨 慎性原则，对合并财务报表范围内的各项需要计提减值的资产进行了评估和分 析，对预计存在可能发生减值损失的相关资产计提减值准备。现将相关情况公告 如下： 一、本次计提减值准备的情况概述 关于 2024 年 1-9 月计提资产减值准备的公告 （一）、本次计提资产减值准备的原因 根据《企业会计准则》和公司会计政策的相关规定，公司对合并范围内截止 2024 年 9 月 30 日的各类资产进行了清查、分析和评估，对部分可能发生信用、 资产减值的资产计提了减值准备。 （二）、本次计提资产减值准备的情况 公司及下属子公司对 2024 年 9 月末存在可能发生减值迹象的资产进行全面 清查和资产减值测试后，计提 2024 年 ...

证券代码：300550 证券简称：和仁科技 公告编号：2024-040 浙江和仁科技股份有限公司 关于注销募集资金专项账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、募集资金的基本的情况 （1）募集资金到位情况 经中国证券监督管理委员会 关于核准浙江和仁科技股份有限公司非公开发 行股票的批复》（证监许可[2020]1243 号）核准，浙江和仁科技股份有限公司非 公开发行 （A 股）股票 25,862,558 股，发行价格为人民币 19.61 元/股，募集资 金总额为 507,164,762.38 元，减除发行费用人民币 10,845,153.28 元后，募集 资金净额为 496,319,609.10 元。天健会计师事务所 （特殊普通合伙）于 2020 年 9 月 30 日对本次发行的资金到位情况进行了审验，并出具了天健验[2020]415 号 验资报告》。 | | | 为规范募集资金的管理和使用，提高资金使用效率和效益，保护投资者利益， 本公司根据 公司法》 证券法》 上市公司监管指引第 2 号——上市公司募集资 金管理和使用的监管要求(202 ...

法律意见书 浙江天册律师事务所 关于 浙江和仁科技股份有限公司 2024 年第二次临时股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于浙江和仁科技股份有限公司 2024 年第二次临时股东大会的 法律意见书 编号：TCYJS2024H1424 号 致：浙江和仁科技股份有限公司 本法律意见书仅供公司 2024 年第二次临时股东大会之目的使用。本所律师同 意将本法律意见书随和仁科技本次股东大会其他信息披露资料一并公告，并依法 对本所在其中发表的法律意见承担法律责任。 本所律师根据《股东大会规则》的要求，按照律师行业公认的业务标准、道德 规范和勤勉尽责的精神，对和仁科技本次股东大会所涉及的有关事项和相关文件 进行了必要的核查和验证，同时听取了公司就有关事实的陈述和说明。现出具法律 意见如下： 一、本次股东大会召集、召开的程序 （一）经本所律师核查，公司本次股东大会由董事会提议并召集，召开本次 股东大会的通知已于 2024 年 8 月 23 日在巨潮资讯网站及深圳证券交 ...

证券代码：300550 证券简称：和仁科技 公告编号：2024-039 浙江和仁科技股份有限公司 2024年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、召开时间： （1）现场会议召开时间：2024年9月9日（星期一）下午15：00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2024年9月9日的交易时间，即9:15—9：25，9：30—11:30 和13:00—15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2024年9月9日9:15至 2024年9月9日15:00期间的任意时间。 2、召开地点：杭州市滨江区新联路625号和仁科技大厦3楼会议室 3、召开方式：本次股东大会采用现场表决与网络投票相结合的方式，公司 股东应选择现场投票、网络投票中的一种方式。同一表决权出现重复投票表决的， 以第一次投票结果为准。 4、召集人：浙江和仁科技股份有限公司董事会 5、主持 ...